Thiol-reducing agents prevent sulforaphane-induced growth inhibition in ovarian cancer cells

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Sulforaphane, a natural compound, shows potential anti-cancer properties against various cancers, including ovarian cancer.
• Mitogen-activated protein kinase (MAPK) pathways and reactive oxygen species (ROS) are key signaling molecules involved in cell survival and proliferation.
• Understanding the precise mechanisms of sulforaphane's action is crucial for its therapeutic application in ovarian cancer.

Purpose of the Study:

• To investigate the role of MAPK pathways and ROS in sulforaphane-mediated growth inhibition of ovarian cancer cells.
• To elucidate the cellular mechanisms underlying sulforaphane's anti-cancer effects in ovarian cancer.

Main Methods:

• Ovarian cancer cells were treated with sulforaphane (10 μM).
• Specific inhibitors were used to assess the involvement of MAPK pathways.
• Intracellular ROS levels were measured.
• The effects of thiol reducers and ROS scavengers on sulforaphane-induced growth inhibition were evaluated.
• The impact of a thiol-oxidizing agent (diamide) on sulforaphane's effects was examined.

Main Results:

• Sulforaphane significantly inhibited ovarian cancer cell growth at 10 μM.
• MAPK pathway activation was not found to mediate sulforaphane-induced growth inhibition.
• Sulforaphane did not induce significant intracellular ROS production.
• Thiol reducers, but not ROS scavengers, prevented sulforaphane's growth inhibitory effects.
• Diamide enhanced sulforaphane-induced growth inhibition and cell death, suggesting a role for thiol oxidation.

Conclusions:

• Sulforaphane's anti-cancer effect in ovarian cancer cells is likely mediated by the oxidation of protein thiols or alterations in cellular redox status, rather than MAPK pathways or ROS.
• Supplementation with thiol-reducing agents should be avoided when using sulforaphane for cancer treatment, as it may counteract its therapeutic benefits.